Table 2. Adverse outcomes by treatment arm in eligible randomized patients.

Outcome variable	Arm 1	Arm 2
	Tamoxifen alone N=149	Tamoxifen+MPA N=147
Breast cancer progression or death	23 (15%)	14 (10%)
Removal from protocol owing to toxicity or worsening illness	16 (11%)	20 (14%)
Positive EMB	5 (3%)	3 (2%)
Total (any event)	40 (27%)	35 (24%)
Total (Positive EMB, progression, or death)	27 (18%)	17 (12%)

Abbreviations: EMB, endometrial biopsy; MPA, medroxyprogesterone acetate.

Patients may have experienced more than one adverse outcome.